Why a New Opioid Alternative Is Out of Reach for some Pain Patients

Why a new opioid alternative is out of reach for some pain patients

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

Why a new opioid alternative is out of reach for some pain patients – DG Verifications & Stats

Earlier this year, the Food and Drug Administration approved the first new kind of painkiller in 20 years. It’s considered an alternative to opioids. But it’s expensive, and not everyone has access to it yet. Vertex Pharmaceuticals Vertex Pharmaceuticals Jerry Abrams, a 64-year-old marketing strategist in Minneapolis, used to run marathons. But two decades of degenerative spine disease have left him unable to run — and he’s grieving. For Abrams,…

Why a new opioid alternative is out of reach for some pain patients - TPR: The Public's Radio

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet. The post Why a new opioid alternative is out of reach for some pain patients appeared first on TPR: The Public's Radio.

Ocular Pain Management in the Opioid Epidemic with Blair Lonsberry, OD

Lonsberry recommends alternative approaches to manage postoperative pain, balancing the need for relief against the risk of addiction and death.

A third of muscular dystrophy patients report moderate pain: Study

Nearly one-third of people with muscular dystrophy (MD) experience moderate pain, which varies by the type of their MD, a study with more than 1,200 participants suggests. To manage their pain, about a fifth of patients used prescribed pain medications, mostly non-opioid therapies at first, then combined with opioids over time. Impaired mobility was the most significant factor associated with using prescription pain medication. “These data highl…